Antimicrobial and Antibacterial Agents

Clayton Dehn is the Sr. V.P., Early Phase Services and Strategic Development at Clinical Trials of Texas, Inc., a multitherapeutic research site based in San Antonio. He is a research physiologist with expertise in endocrine and metabolic disorders. He is the co-inventor of a process and substance for disturbing the inheritance pattern of ion-channelopathic disorders, and the sole author of the first publication cautioning against the risk of SGLT-inhibition inducing ketoacidosis in insulinopenic populations. In addition to serving on the editorial board of three peer-reviewed journals, he has also served by gubernatorial appointment on the Arizona Biomedical Research Commission

Clinical Research | Early signals of efficacy to streamline the drug development process